Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim that olanzapine is associated with increased mortality in elderly patients with dementia-related psychosis is directly supported by the provided FDA label excerpts (Boxed Warning, Section 5.1, and Section 8.5). No contradictions or unsafe omissions were identified for the scope of the claim.
Category Scores
Accurate Statements
Increased mortality (elderly patients with dementia-related psychosis treated with antipsychotic drugs, including olanzapine) is supported by the FDA label.
Boxed Warning: increased risk of death vs placebo; Sections 5.1 and 8.5 reiterate increased incidence/risk in elderly dementia-related psychosis treated with olanzapine.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Evaluation limited to the single claim about increased mortality risk in the specified population, which is directly supported by the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement